Typical lesions progress from red or gray macules or papules, to red or gray macules or papules with a central eschar or ulceration ... Panafil® was applied to the wound to loosen the necrotic ...

MediWound (MDWD) shares ended the last trading session 8.5% higher at $19.83. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their Oppenheimer representative to schedule a meeting.

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...